Escalon Medical Corp (ESMC) stock
ESMCOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Oct 13, 2026Score 10/30
$0.18+0.01 (+7.65%)
Close on Oct 19, 2026Market cap $2.72MP/E 0.7Yield –
Escalon Medical r&d expenses
Research and development expenses are spending on new products and technology.
Escalon Medical's R&D Expenses for the twelve months ending Jun 30, 2026 was $501.49K, down 33.4% year over year. For fiscal 2026 it was $501.49K, down 33.4% from the year before. Over ten years it grew -10.1% a year on average. The highest annual figure on record is $1.60M in fiscal 2011.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $501.49K | -33.4% |
| FY2025 | Jun 30, 2025 | $753.13K | +9.4% |
| FY2024 | Jun 30, 2024 | $688.19K | -15.9% |
| FY2023 | Jun 30, 2023 | $818.77K | -17.4% |
| FY2022 | Jun 30, 2022 | $990.98K | +11.3% |
| FY2021 | Jun 30, 2021 | $890.48K | -20.7% |
| FY2020 | Jun 30, 2020 | $1.12M | +51.7% |
| FY2019 | Jun 30, 2019 | $739.77K | +47.9% |
| FY2018 | Jun 30, 2018 | $500.33K | -52.5% |
| FY2017 | Jun 30, 2017 | $1.05M | -27.4% |
| FY2016 | Jun 30, 2016 | $1.45M | +11.4% |
| FY2015 | Jun 30, 2015 | $1.30M | -0.4% |
| FY2014 | Jun 30, 2014 | $1.31M | +18.2% |
| FY2013 | Jun 30, 2013 | $1.11M | +10.0% |
| FY2012 | Jun 30, 2012 | $1.00M | -37.3% |
| FY2011 | Jun 30, 2011 | $1.60M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $124.30K | -57.4% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $29.91K | -81.8% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $131.18K | -15.9% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $216.10K | +53.4% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $291.58K | +68.6% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $164.76K | +5.7% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $155.94K | +5.6% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $140.86K | -33.4% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $172.98K | -2.5% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $155.85K | -16.1% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $147.72K | -22.8% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $211.65K | -19.9% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $177.45K | -15.5% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $185.75K | -19.0% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $191.33K | -26.5% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $264.24K | -9.3% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $210.04K | -4.9% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $229.32K | +6.3% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $260.44K | +6.5% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $291.19K | +39.1% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $220.93K | -29.6% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $215.70K | -28.3% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $244.53K | -6.6% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $209.32K | -14.8% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $313.90K | +57.7% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $301.03K | +38.1% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $261.76K | +15.6% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $245.64K | +154.8% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $199.01K | +85.8% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $218.01K | +135.3% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $226.34K | +110.5% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $96.41K | -50.1% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $107.10K | -39.5% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $92.65K | -66.9% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $107.51K | -62.4% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $193.08K | -37.8% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $177.06K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $279.88K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $286.14K | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $310.36K | – |
See a number that looks wrong?